CNC SEC Filings

Centene Corporation (CNC) has announced a significant leadership transition in its finance department. Effective December 31, 2026, Chief Financial Officer Andrew Asher will retire from his role but will continue to support the company as a Strategic Advisor through the end of 2027 to ensure a smooth handover and assist with strategic initiatives. This transition is designed to leverage Mr. Asher's experience during a crucial period. To ensure continuity and bring in fresh expertise, Centene has appointed Christopher Neczypor as the successor CFO, effective January 1, 2027. Mr. Neczypor brings substantial financial and strategic experience, including prior CFO and Chief Strategy Officer roles at Lincoln National Corporation, and a background in investment management focused on the insurance sector. His appointment is accompanied by a comprehensive employment agreement outlining his compensation and responsibilities leading up to and following his official CFO tenure, including an initial Executive Vice President role starting September 1, 2026.

Centene Corporation (CNC) has announced a partial redemption of its 4.25% Notes due December 15, 2027. The company intends to redeem $500,000,000 of these notes on August 13, 2026. This action will reduce the outstanding principal amount of the 2027 Notes to approximately $568,664,000 following the redemption. Investors holding these notes should be aware that their principal investment will be partially repaid at par plus any accrued interest up to the redemption date. This move signals a potential shift in Centene's capital structure or debt management strategy, and investors should monitor any further announcements regarding the use of cash or changes in debt levels.

Centene Corporation (CNC) reported strong financial results for the second quarter and first half of 2026, demonstrating significant year-over-year improvements. Total revenues grew 10% to $53.6 billion for the quarter and 9% to $103.5 billion for the first half, driven by increased premium tax revenue, higher premium yields, and rate adjustments across its Medicaid and Marketplace segments. The company also saw substantial growth in its Medicare Prescription Drug Plan (PDP) business. Profitability improved markedly, with net earnings of $1.09 billion ($2.19 diluted EPS) in Q2 2026, a significant turnaround from a loss in the prior year. For the first half, net earnings were $2.63 billion ($5.30 diluted EPS). This improvement is attributed to a lower Health Benefits Ratio (HBR) of 89.6% in Q2 2026 (down from 93.0% in Q2 2025) and a stable Selling, General, and Administrative (SG&A) expense ratio. The company also managed its debt effectively, repurchasing over $1.3 billion in senior notes during the first half of the year. Overall, Centene appears to be successfully navigating industry challenges and executing its strategic initiatives.

Centene Corporation (CNC) filed an 8-K on July 28, 2026, primarily to disclose its financial results for the second quarter ended June 30, 2026, via a press release (Exhibit 99.1). While the specific financial details are not within this excerpt, the filing indicates that an earnings announcement has been made. Additionally, the company announced a change in its Board of Directors. Director Kenneth Burdick resigned from the Board and the Quality and Compliance Committee, effective July 28, 2026. His resignation was stated to be amicable and not due to any disputes. Following Mr. Burdick's resignation, Centene elected Paul Diaz to the Board, effective July 28, 2026, with his term extending to the 2027 annual meeting. Mr. Diaz brings extensive experience in the healthcare sector, having held leadership positions at Kindred Healthcare, Myriad Genetics, and currently serves as a Managing Partner at Cressey & Company. He has been appointed to serve on the Audit Committee and the Quality and Compliance Committee, adding valuable expertise to the company's governance.

Centene Corporation (CNC) announced a change to its Board of Directors with the appointment of Lauren Tyler, effective June 19, 2026. The Board's size has been expanded from 9 to 10 members to accommodate this new director. Ms. Tyler brings extensive experience from her over two-decade tenure at JPMorgan Chase & Co., where she held senior roles including Global Head of Human Resources for its Asset & Wealth Management Division and Global Firmwide Chief Auditor. Her prior experience also includes serving as Global Firmwide Head of Investor Relations. This appointment is significant as Ms. Tyler is expected to contribute to key board committees, specifically the Audit Committee and the Compensation and Talent Committee, starting July 1, 2026. Her existing board memberships at Cencora, Inc. and Guardian Life further underscore her qualifications. Investors should note that Ms. Tyler's appointment does not involve any undisclosed arrangements or related party transactions, and she will be compensated under the company's standard non-employee director program.

Centene Corporation (CNC) filed an 8-K on May 15, 2026, detailing the outcomes of its Annual Meeting of Stockholders held on May 12, 2026. The report confirms the election of all nine director nominees for a one-year term, with strong support across the board. Additionally, shareholders provided a non-binding advisory vote of approval for the company's executive compensation and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Of note, a shareholder proposal requesting an independent board chairman was not approved. The filing also clarifies the company's executive officer positions following recent appointments, with Sarah London continuing as CEO and key leadership roles in Medicaid, Medicare, and other operational areas outlined.

Centene Corporation (CNC) has filed an 8-K report on April 28, 2026, to announce its financial results for the first quarter ended March 31, 2026. The primary purpose of this filing is to provide investors with key financial performance data for the period. While the 8-K itself does not contain the detailed financial results, it references an attached press release (Exhibit 99.1) which serves as the primary source of this information. Investors should refer to the press release furnished as Exhibit 99.1 for comprehensive details on Centene's first-quarter performance. It's important to note that the information in this 8-K and its exhibits is considered "furnished" and not "filed" under the Securities Exchange Act of 1934. This means it is not subject to the same liability provisions as formally filed documents, although it is still a crucial source of timely information for market participants.

Centene Corporation (CNC) reported a strong first quarter for 2026, demonstrating significant growth in total revenues, up 7% year-over-year to $49.9 billion. This revenue increase was primarily driven by growth in its Medicare Prescription Drug Plan (PDP) business and rate increases in its Medicaid segment, despite a slight overall decrease in managed care membership. The company's profitability also saw a notable improvement, with net earnings attributable to Centene Corporation increasing by 18% to $1.54 billion, and diluted EPS rising to $3.11. Key to this performance was effective cost management, reflected in a slight improvement in the Health Benefits Ratio (HBR) to 87.3% and a decrease in the Selling, General, and Administrative (SG&A) expense ratio to 7.6%. The company also generated substantial operating cash flow of $4.4 billion, indicating strong operational liquidity. Centene's strategic initiatives, including the partial sale of its Part D risk-sharing program receivables and continued focus on integrated care through Dual Eligible Special Needs Plans (D-SNPs), position it well for future growth. However, investors should note the ongoing regulatory changes impacting the healthcare landscape, particularly in the Medicaid and Marketplace segments, which continue to influence membership trends and market dynamics.

Centene Corporation (CNC) announced a key leadership transition within its finance department, effective March 18, 2026. Theodore Pienkos has been appointed as the new Corporate Controller and Chief Accounting Officer. Mr. Pienkos is a seasoned executive with a long tenure at Centene, having held various accounting and finance roles since 2011, including Deputy Corporate Controller since August 2024. His extensive experience, including his background as a CPA and former auditor at KPMG, positions him well to oversee the company's accounting functions. In parallel, Kate Casso, the former Corporate Controller and Chief Accounting Officer, has been appointed to the newly created role of Senior Vice President, Finance Operations and Innovation. This move reflects Centene's focus on leadership development and strategic innovation. Ms. Casso will leverage her deep understanding of the company, gained over two decades of service, to drive improvements in finance operations, data analytics, and innovation initiatives, while continuing to oversee critical finance teams. Investors can view these changes as positive steps towards strengthening financial oversight and fostering future growth.

Centene Corporation has filed an 8-K report on March 10, 2026, primarily to provide an update ahead of their presentation at the Barclays 28th Annual Global Healthcare Conference. The key takeaway for investors is the reaffirmation of the company's previously issued 2026 full-year financial guidance. Centene expects to achieve GAAP diluted earnings per share (EPS) greater than $1.98 and adjusted diluted EPS greater than $3.00, signaling confidence in their operational performance and outlook for the remainder of the fiscal year. In addition to reaffirming guidance, the report disclosed Centene's intention to partially redeem its outstanding 4.25% Notes due December 15, 2027. The company plans to redeem $1,000,000,000 in aggregate principal amount of these notes on March 25, 2026, with approximately $1,186,664,000 of the notes remaining outstanding. This action suggests a proactive approach to managing its debt obligations and capital structure.

Centene Corporation (CNC) has filed an 8-K on February 23, 2026, primarily to disclose that its senior management team will be meeting with investors. During these meetings, the company intends to reaffirm its previously issued full-year 2026 guidance. This includes reiterating its GAAP diluted earnings per share (EPS) guidance of greater than $1.98 and its adjusted diluted EPS guidance of greater than $3.00. This reaffirmation suggests confidence in the company's financial trajectory for the remainder of the fiscal year, aligning with prior expectations despite potential market fluctuations. The filing also includes standard Forward-Looking Statements and a Non-GAAP Financial Presentation section. Centene emphasizes that its non-GAAP measures, which exclude items like amortization of acquired intangible assets and acquisition-related expenses, are provided to offer investors a clearer view of the ongoing operational performance and to facilitate more consistent period-to-period comparisons. Investors are advised to review GAAP financials in conjunction with these non-GAAP measures, as they may not be directly comparable to other companies' reporting.

Centene Corporation (CNC) reported its 2025 fiscal year results, characterized by significant revenue growth and a substantial increase in medical costs. Total revenues reached $194.8 billion, a 19% increase year-over-year, driven by membership growth in the PDP business, marketplace expansion, and Medicaid rate increases. However, the Health Benefits Ratio (HBR) rose to 91.9% from 88.3% in the prior year, largely due to lower marketplace risk adjustment revenue, increased marketplace medical costs, and higher medical costs in Medicaid, particularly in behavioral health, home health, and high-cost drugs. A notable event for 2025 was the substantial goodwill impairment of $6.7 billion, primarily impacting the Medicaid and Commercial reporting units, contributing to a GAAP diluted loss per share of $(13.53). Adjusted diluted EPS stood at $2.08. The company also experienced a decrease in overall membership by 3% to 27.6 million, largely due to Medicaid redeterminations. Despite these challenges, Centene's operating cash flow improved significantly to $5.1 billion, and the company continued to manage its debt, with $1.8 billion remaining under its stock repurchase program as of year-end.

Centene Corporation (CNC) has filed an 8-K on February 6, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. The filing primarily serves to attach the press release detailing these results and a presentation outlining the company's guidance for the full year 2026. Investors should refer to the attached exhibits (99.1 and 99.2) for the specific financial performance and forward-looking statements.

Centene Corporation (CNC) has issued an 8-K filing on November 10, 2025, to announce its participation in the UBS 2025 Global Healthcare Conference on November 11, 2025. During this conference and subsequent investor discussions, management will provide commentary on the company's financial outlook. Importantly, this outlook remains consistent with the previously issued full-year 2025 guidance. Specifically, Centene reaffirms its full-year 2025 GAAP forecast of a diluted loss per share not exceeding $(12.85). Concurrently, the company reiterates its adjusted diluted EPS forecast for the full year 2025 to be at least $2.00. The filing also clarifies the company's use of non-GAAP financial measures, emphasizing their utility in assessing ongoing operations and performance consistency, while strongly encouraging investors to review their full GAAP financial statements. Centene also includes its standard forward-looking statements disclaimer, outlining various risks and uncertainties that could affect future performance.

Centene Corporation (CNC) reported a significant net loss of $6.63 billion for the third quarter of 2025, primarily driven by a substantial non-cash goodwill impairment charge of $6.7 billion. This impairment was attributed to evolving market conditions, including potential membership impacts from the 'One Big Beautiful Bill Act' and changes in Marketplace enhanced Advance Premium Tax Credits. Despite the GAAP loss, the company reported an adjusted diluted EPS of $0.50, indicating operational profitability excluding the impairment. Total revenues saw robust growth of 18% year-over-year to $49.7 billion, fueled by strong performance in the Prescription Drug Plan (PDP) business, market growth in the Health Insurance Marketplace, and increased Medicaid rates. However, the Health Benefits Ratio (HBR) increased to 92.7% from 89.2% in the prior year, reflecting higher medical costs in Marketplace and Medicaid segments, as well as impacts from the Inflation Reduction Act on the PDP business. The company's strategic focus remains on managing medical costs, adapting to regulatory changes, and driving operational efficiency, as evidenced by an improved SG&A expense ratio.

Centene Corporation (CNC) has filed an 8-K report on October 29, 2025, to announce its financial results for the third quarter ended September 30, 2025. The key details of these results are provided in an attached press release (Exhibit 99.1). Investors should note that while this information is being disclosed, it is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same liability implications as a formally filed document. This filing serves as the primary vehicle for disseminating CNC's latest quarterly performance. Investors seeking specific financial metrics such as revenue, earnings per share, and any forward-looking guidance or management commentary will need to refer to the content of the Exhibit 99.1 press release. The company has chosen to report these results via a press release, which is standard practice for earnings announcements, and the 8-K serves to formally submit that release to the SEC.

Centene Corporation (CNC) announced via an 8-K filing on September 11, 2025, that management will participate in the Deutsche Bank 2025 Healthcare Summit. During this presentation, the company reiterated its full-year 2025 adjusted diluted earnings per share (EPS) forecast of approximately $1.75. This confirms that current business performance through August is tracking in line with the company's prior guidance, providing a degree of stability for investors amidst ongoing market dynamics. The filing also provided context on the use of non-GAAP financial measures, emphasizing their utility in assessing ongoing operational performance and consistency across periods. While not providing specific reconciliations for the EPS forecast to GAAP measures, Centene highlighted that these non-GAAP figures, excluding items like amortization of acquired intangibles and acquisition-related expenses, offer a clearer view of core business operations. Investors are encouraged to review the full GAAP financial statements alongside these non-GAAP metrics.

Centene Corporation (CNC) announced the resignation of Director Thomas R. Greco, effective August 22, 2025. Mr. Greco's departure is attributed to his increased professional commitments following his recent appointment as CEO of FleetPride, Inc., a privately-held company. Importantly, the company stated that his resignation is not due to any disagreements with Centene's management or Board of Directors regarding the company's operations, policies, or practices. This change will result in a reduction of the Board's size from ten to nine directors.

Centene Corporation (CNC) announced a notable change in its Board of Directors with the immediate resignation of Director Wayne S. DeVeydt, effective August 1, 2025. The company explicitly stated that Mr. DeVeydt's departure was not due to any disagreements regarding the company's operations, policies, or practices. This development has led to a reduction in the size of the Board, now comprising ten directors.

Centene Corporation (CNC) reported a net loss of $0.51 per diluted share for the second quarter of 2025, a significant decline from the $2.16 earnings per share in the same period last year. This downturn was primarily attributed to a reduction in the estimated net 2025 Marketplace risk adjustment revenue transfer, alongside increased medical costs in both the Marketplace and Medicaid segments. Total revenues saw a substantial 22% year-over-year increase to $48.7 billion, driven by strong performance in the Medicare Prescription Drug Plan (PDP) business and growth in the Health Insurance Marketplace, alongside rate increases in Medicaid. Despite revenue growth, the company's Health Benefits Ratio (HBR) rose to 93.0% from 87.6% in the prior year's second quarter, indicating higher medical costs relative to premium revenues. This was partially offset by an improvement in the Selling, General & Administrative (SG&A) expense ratio to 7.1% from 8.0%, reflecting better cost leverage over increased revenues. The company's liquidity remains solid, with cash flows from operations providing $3.3 billion for the first six months of 2025, and a substantial $1.8 billion remaining under its stock repurchase authorization.

Centene Corporation (CNC) has filed an 8-K report on July 25, 2025, to announce its financial results for the second quarter ended June 30, 2025. This filing primarily directs investors to the press release (Exhibit 99.1) for detailed information on the company's operational performance and financial condition during the quarter. While the 8-K itself does not contain the financial figures, it serves as the official notification of their release.

Centene Corporation (CNC) announced on July 1, 2025, through an 8-K filing, that it has withdrawn its previously issued 2025 GAAP and adjusted diluted earnings per share (EPS) guidance. This withdrawal includes all underlying guidance elements. The company has not provided any revised guidance in this filing. Investors should note that this is a significant change from prior expectations and will likely lead to increased scrutiny of the company's future performance and outlook. The reasons for the withdrawal of guidance are not detailed within the 8-K filing itself, but the full press release containing this information is incorporated by reference.

Centene Corporation (CNC) filed an 8-K detailing the outcomes of its Annual Meeting of Stockholders held on May 13, 2025. The filing indicates strong shareholder support for the company's slate of directors, with all eleven nominees receiving a significant majority of the votes cast for their election to a one-year term. This outcome suggests continued confidence from investors in the current leadership and governance of the company. Furthermore, shareholders provided advisory approval for the company's executive compensation structure and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposed 2025 Stock Incentive Plan also received shareholder approval, indicating support for management's equity-based compensation strategies. Notably, two shareholder proposals related to climate change disclosure and reporting were not approved.

Centene Corporation (CNC) filed an 8-K on May 6, 2025, primarily to reaffirm its financial guidance for the full year 2025. The company's senior management will meet with investors and plans to confirm the previously provided guidance floors for both GAAP diluted Earnings Per Share (EPS) of greater than $6.19 and adjusted diluted EPS of greater than $7.25. This reaffirmation suggests management's confidence in the company's operational performance and ability to meet its financial targets for the year. The filing also elaborates on Centene's use of non-GAAP financial measures. The company emphasizes that these measures, which exclude items like amortization of acquired intangible assets and acquisition/divestiture related expenses, are provided to offer investors a clearer view of the ongoing operational performance and to facilitate more consistent period-to-period comparisons. While Centene believes these non-GAAP figures are valuable for understanding core business operations, it strongly encourages investors to review its full GAAP financial statements and filings, noting that non-GAAP measures may differ from those used by other companies.

Centene Corporation (CNC) has filed an 8-K report on April 25, 2025, to announce its financial results for the first quarter ended March 31, 2025. The key details of these results are contained within the press release attached as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profitability, and any forward-looking guidance provided by the company for the upcoming periods. While the 8-K itself is brief and primarily serves as a notification of the press release, the attached exhibit is the critical document for understanding Centene's recent performance. The company is providing this information to comply with reporting requirements and ensure timely disclosure to the market. Investors should carefully review the press release for any changes in business trends, operational updates, or management commentary that could impact the company's valuation and future prospects.

Centene Corporation (CNC) reported strong first-quarter 2025 results, demonstrating robust revenue growth and improved profitability. Total revenues surged by 15% year-over-year to $46.6 billion, driven primarily by significant expansion in the Medicare Prescription Drug Plan (PDP) and Health Insurance Marketplace (Ambetter Health) businesses. Despite a slight increase in the Health Benefits Ratio (HBR) due to seasonal factors in Medicaid, the company effectively managed expenses, leading to a decrease in the SG&A expense ratio and a substantial 39% increase in operating earnings. Net earnings attributable to Centene Corporation rose 13% to $1.31 billion, with diluted earnings per share (EPS) increasing by 22% to $2.63. The company also reported strong operating cash flows of $1.5 billion. Management highlighted strategic wins in contract renewals and expansions across its Medicaid segment, alongside growth in its Medicare and Commercial businesses, positioning Centene favorably for future performance amidst evolving healthcare regulations.

Centene Corporation (CNC) has filed an 8-K to announce their participation in the Barclays 27th Annual Global Healthcare Conference on March 12, 2025. The primary takeaway for investors is the company's reaffirmation of its previously issued 2025 adjusted diluted earnings per share (EPS) annual guidance of greater than $7.25. This signals management's confidence in their financial performance for the upcoming year, despite the inherent risks and uncertainties associated with the healthcare industry and the company's operations. The filing also reiterates Centene's use of non-GAAP financial measures, such as adjusted diluted EPS, to provide a clearer view of ongoing operational performance. While the company believes these measures are valuable for investors, it also cautions that they may differ from those used by other companies and encourages a comprehensive review of all SEC filings. The forward-looking statements section highlights a broad range of potential risks and uncertainties that could impact future results, covering regulatory changes, competition, operational challenges, and economic conditions.

Centene Corporation (CNC) has announced the execution of a new Senior Unsecured Credit Facility, replacing its previous credit agreement. This new facility totals $6 billion, comprising a $4 billion revolving credit facility and a $2 billion term loan facility, with a maturity date set for March 5, 2030. The company simultaneously terminated its existing credit agreement and repaid outstanding obligations, indicating a proactive refinancing effort. The new credit agreement provides Centene with significant financial flexibility, allowing for borrowings in multiple currencies and offering voluntary prepayments without penalty. Key covenants include a debt-to-capital ratio not exceeding 0.60:1.00, with a potential step-up to 0.65:1.00 following a material acquisition. The proceeds from the term loan were used for refinancing existing debt, transaction-related expenses, and general corporate purposes, including working capital. This move is likely aimed at optimizing Centene's capital structure and securing more favorable terms for its long-term financing.

Centene Corporation (CNC) filed an 8-K on March 4, 2025, primarily to disclose that its senior management will be meeting with investors. A key takeaway from this disclosure is the reaffirmation of the Company's previously issued 2025 full-year adjusted diluted earnings per share (EPS) guidance floor of greater than $7.25. This confirmation provides investors with continued confidence in the company's profitability outlook for the current year. The filing also emphasizes Centene's use of non-GAAP financial measures, such as excluding amortization of acquired intangible assets and acquisition/divestiture related expenses, to provide a clearer view of ongoing operational performance. While the company believes these measures offer meaningful insights for assessing consistent performance across periods, investors are encouraged to review the full GAAP financial statements and understand that these non-GAAP figures may differ from those presented by other companies. The company also noted the difficulty in reconciling its forward-looking adjusted EPS guidance to GAAP measures without unreasonable effort.

Centene Corporation (CNC) announced a change to its Board of Directors, appointing Kenneth Tanji as a new independent director, effective February 20, 2025. The Board's size has been expanded to accommodate this appointment, and Mr. Tanji will serve on the Audit and Compliance Committee. This addition brings a wealth of financial expertise to the board, with Mr. Tanji's extensive background as a former CFO of Prudential Financial and his current roles on other public company boards and as a university professor. Investors should view this as a positive move to strengthen the board's oversight capabilities, particularly in financial matters. The appointment of Mr. Tanji, who has no stated arrangements or related party transactions with the company, is intended to enhance the board's collective experience and governance. His term as a director will run until the company's 2025 annual meeting of stockholders. The press release detailing this announcement is incorporated into the filing, providing further context for shareholders.

Centene Corporation reported solid financial performance for the year ended December 31, 2024, with total revenues increasing by 6% to $163.1 billion and net earnings attributable to Centene rising by 22% to $3.3 billion. This growth was driven by a 4% increase in total membership to 28.6 million, largely fueled by expansion in the Health Insurance Marketplace segment. The company's strategic focus on government-sponsored healthcare programs continues to be its core, with Medicaid representing 62% of its total external revenues. Despite overall revenue growth, the Health Benefits Ratio (HBR) saw a slight increase to 88.3% from 87.7% in the prior year, primarily due to higher acuity in the Medicaid population following redeterminations and impacts from Medicare Star rating changes. However, an improved Selling, General, and Administrative (SG&A) expense ratio of 8.5% helped offset some of these pressures.

Centene Corporation (CNC) has filed an 8-K report on February 4, 2025, primarily to announce its financial results for the fourth quarter and the full year ended December 31, 2024. The core of this filing is the press release included as Exhibit 99.1, which provides the detailed financial performance metrics for the period. Investors should refer to this press release for specific figures regarding revenue, profitability, and other key operational indicators, as well as any forward-looking statements or guidance issued by the company. This 8-K serves as a crucial notification of the company's latest financial status. While the 8-K itself contains limited narrative, the attached press release is the primary source for understanding Centene's performance and outlook. Investors are advised to examine the press release carefully for any material changes or trends that could impact the company's valuation and future prospects. It's important to note that the information furnished in this 8-K and its exhibits is generally not considered 'filed' for regulatory purposes, meaning it doesn't trigger the same liabilities under Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated into other filings.

Centene Corporation (CNC) has filed an 8-K on December 12, 2024, primarily to disclose its 2025 financial guidance and reaffirm its 2024 guidance. This filing indicates the company is providing forward-looking financial targets for the upcoming fiscal year, which is a key event for investors assessing the company's future performance and strategic direction. Investors should pay close attention to the details of this guidance, as it will shape expectations for revenue, profitability, and operational metrics throughout 2025. Additionally, Centene hosted a virtual investor day on the same date, providing a platform for deeper discussion and Q&A regarding their financial outlook and business strategies. The reaffirmation of 2024 guidance suggests confidence in achieving current year targets, while the new 2025 guidance will be critical for understanding the company's growth trajectory and potential challenges or opportunities.

Centene Corporation (CNC) has filed an 8-K report on November 13, 2024, to disclose that its senior management team will be meeting with investors. During these meetings, the company intends to reaffirm its previously issued full-year 2024 adjusted diluted Earnings Per Share (EPS) guidance of greater than $6.80. This reaffirms their confidence in their operational performance and financial targets for the current fiscal year. Furthermore, Centene also plans to reiterate its positive outlook for the future by stating that the company expects to achieve growth in adjusted diluted EPS for 2025 and beyond. This forward-looking statement signals the company's strategic focus on sustained growth and profitability, aiming to provide investors with confidence in the company's long-term trajectory.

Centene Corporation (CNC) announced a significant leadership transition via an 8-K filing on November 12, 2024. Kenneth J. Fasola, President of the company, has informed the Board of his intention to retire effective July 1, 2025. This announcement marks the end of Mr. Fasola's impactful 40-year career in healthcare, with a substantial portion spent at Centene. Leading up to his retirement, Mr. Fasola will focus on transitioning his current responsibilities to ensure a smooth handover of duties. Following this transition period, he will serve as a Strategic Advisor to the CEO, Sarah M. London, until his final retirement. This arrangement will allow Centene to leverage Mr. Fasola's extensive experience during this interim period. Investors should monitor the company's succession planning and the integration of Mr. Fasola's former duties by the executive team.

Centene Corporation (CNC) has filed an 8-K report on October 25, 2024, primarily to announce its third-quarter financial results for the period ending September 30, 2024. The details of these results are provided in a press release, which is included as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, operational achievements, and management's commentary on the quarter. This filing serves as the official notification of the Q3 2024 results. It's important for investors to note that the information within this 8-K and its attached press release is furnished and not filed, meaning it does not carry the same legal implications under Section 18 of the Securities Exchange Act of 1934. However, the press release itself contains the substantive financial information and outlook that investors will be analyzing to assess Centene's current performance and future prospects.

Centene Corporation (CNC) reported a mixed financial performance for the third quarter and first nine months of 2024. Total revenues showed robust year-over-year growth, driven by strong performance in the Commercial (Marketplace) segment and increased premium tax revenue, partially offset by declines in Medicaid membership due to redeterminations and divestitures in the 'Other' segment. While overall revenue grew, the company experienced a higher Health Benefits Ratio (HBR) primarily due to increased acuity in Medicaid and Medicare Star rating impacts, leading to a decrease in gross margin across Medicaid and Medicare segments. Despite these challenges, the company's net earnings and diluted EPS saw significant year-over-year increases for the quarter, though adjusted diluted EPS declined. This improvement in GAAP EPS was aided by lower income tax expense and strong investment income, as well as the absence of significant impairment charges seen in the prior year. The company continues its strategic initiatives, including geographic expansion in its Commercial business and managing its Medicare Advantage strategy despite challenges from Star ratings. Liquidity remains solid, supported by operating cash flows and a substantial stock repurchase program authorization.

Centene Corporation (CNC) announced an improvement in its 2025 Medicare Advantage Star Ratings, with approximately 46% of its Medicare Advantage membership now enrolled in plans rated 3.5 stars or higher. This marks a significant increase from the prior year's 23% and aligns with the company's internal expectations, even in the face of higher-than-industry-anticipated cut point changes by the Centers for Medicare and Medicaid Services (CMS). This progress in Star Ratings is crucial for Centene, as higher ratings directly impact revenue and future growth potential. The company is also pursuing an appeal with CMS regarding its TTY (Teletypewriter) results, indicating a proactive approach to addressing all potential rating factors. Investors should monitor Centene's ongoing efforts to improve its quality scores and the outcome of the TTY appeal, as these factors are material to the company's financial performance and competitive positioning in the Medicare Advantage market.

Centene Corporation (CNC) filed an 8-K on October 3, 2024, primarily detailing a change in board committee appointments. Thomas R. Greco has been appointed to both the Governance Committee and the Compensation and Talent Committee of the Board. This filing does not appear to contain information regarding significant financial performance, strategic shifts, or executive departures that would materially impact investor outlook in the short term. Investors should note that committee appointments, while important for corporate governance, are typically administrative and do not signal immediate changes in operational strategy or financial results.

Centene Corporation (CNC) filed an 8-K on September 27, 2024, to report a change in its Board of Directors. Director Lori J. Robinson has informed the company that she will not seek re-election at the upcoming 2025 Annual Meeting. This decision marks the end of her five-year tenure on the board. While this is a routine change, investors should note any potential implications for board composition and governance. The company expressed gratitude for Director Robinson's service, suggesting a positive departure. Investors may want to monitor future board appointments and any strategic shifts that could accompany leadership changes.

Centene Corporation (CNC) has filed an 8-K to disclose information related to upcoming investor meetings and its financial guidance. The company will be meeting with investors on September 17, 2024, and presenting at the Bank of America 2024 Global Healthcare Conference on September 18, 2024. During these engagements, Centene expects to reaffirm its full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80. The filing also emphasizes Centene's use of non-GAAP financial measures, such as adjusted diluted EPS, to provide a clearer view of ongoing operational performance and to facilitate consistent period-to-period comparisons. The company believes these measures, which exclude items like amortization of acquired intangible assets and acquisition-related expenses, offer meaningful insights into its core business. However, Centene cautions investors that these non-GAAP measures may differ from those used by other companies and should be reviewed alongside GAAP financial information. A reconciliation of the 2024 adjusted diluted EPS guidance to the comparable GAAP measure is not provided due to the difficulty in predicting certain timing and amounts of non-recurring items.

Centene Corporation (CNC) filed an 8-K on September 10, 2024, to disclose information from an investor meeting. The key takeaway for investors is the reaffirmation of the company's full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80. This indicates management's confidence in achieving its previously stated financial targets for the year. The filing also reiterates a shift in EPS realization from the third quarter (Q3) to the fourth quarter (Q4) of 2024, with Q3 adjusted diluted EPS projected to be between $1.31 and $1.41. The company further noted positive progress in improving its Medicare Advantage Stars program performance, a key area for future growth and revenue enhancement within its government-backed health insurance offerings.

Centene Corporation (CNC) announced on August 15, 2024, a change in its Board of Directors, effective August 9, 2024. The Board has been expanded from 10 to 11 members with the appointment of Thomas Greco. Mr. Greco brings extensive executive leadership experience, having previously served as CEO of Advance Auto Parts, Inc. and CEO of Frito-Lay North America, a division of PepsiCo, Inc. His appointment is intended to leverage his significant operational and strategic expertise. Mr. Greco's background includes a 30-year tenure at PepsiCo in various leadership roles and current board service with Tapestry, Inc. and Sabra Dipping Company LLC. He will participate in the company's standard compensation program for non-employee directors. This appointment appears to be a strategic move to enhance board oversight and governance, with no undisclosed arrangements or related party transactions identified.

Centene Corporation (CNC) reported its second quarter 2024 financial results, demonstrating revenue growth and improved profitability driven by expansion in its Commercial Marketplace business and effective cost management. Total revenues rose by 6% year-over-year to $39.8 billion, with premium and service revenues showing a 3% increase. The company achieved a Health Benefits Ratio (HBR) of 87.6% and an SG&A expense ratio of 8.0%, indicating operational efficiency. Key growth drivers include a 34% year-over-year increase in Commercial Marketplace membership, now available in 29 states, and a 47% surge in Medicare Prescription Drug Plan (PDP) membership. While Medicaid membership saw a decline due to ongoing eligibility redeterminations, Centene is well-positioned to capture members transitioning to other coverage options. The company also reported strong earnings per share (EPS) of $2.16, up from $1.92 in the prior year, and maintained a solid liquidity position with $5.7 billion in working capital.

Centene Corporation (CNC) has filed an 8-K on July 26, 2024, to report its financial results for the second quarter ended June 30, 2024. The primary focus of this filing is the accompanying press release (Exhibit 99.1), which contains the detailed financial performance for the period. Investors should review this press release for specific figures related to revenue, earnings, and any forward-looking guidance or commentary provided by management. While this 8-K itself does not contain extensive operational details, it serves as the official notification of the release of the Q2 2024 earnings announcement. The press release is expected to offer insights into the company's performance across its various business segments, including Medicare, Medicaid, and the Health Insurance Marketplace, and may provide updates on strategic initiatives or market conditions impacting the company. Investors are advised to consult Exhibit 99.1 for the comprehensive financial data and management's perspective.

Centene Corporation (CNC) has filed an 8-K report on July 23, 2024, primarily addressing the finalization of 2023 risk adjustment transfers by the Centers for Medicare and Medicaid Services (CMS). Initially, Centene had recorded a $1.3 billion payable related to the 2023 benefit year. However, the final CMS determination resulted in a $0.0 billion receivable, leading to a significant positive financial impact for Centene. This favorable outcome is primarily due to a net outperformance from the 2023 risk adjustment calculation, partially offset by an increase in Minimum Medical Loss Ratio (MLR) payable and estimated other offsets from competitors' insolvencies. The company is also providing preliminary second quarter 2024 financial results, expecting GAAP diluted EPS of $2.16 and adjusted diluted EPS of $2.42. These figures include the positive impact of the 2023 risk adjustment outperformance. Centene expects to reaffirm its full-year 2024 guidance, with a floor of greater than $5.94 for GAAP diluted EPS and greater than $6.80 for adjusted diluted EPS. Investors should note that these are preliminary results for Q2 2024 and actual results may differ.

Centene Corporation (CNC) filed an 8-K on May 29, 2024, to provide updates ahead of their investor meetings and the Bernstein Strategic Decisions Conference. The company is expected to reaffirm its full-year 2024 guidance for adjusted diluted EPS to be greater than $6.80 and a consolidated health benefits ratio between 87.3% and 87.9%. While reaffirming guidance, Centene highlighted some key intra-quarter insights that warrant investor attention. Specifically, the company noted higher-than-expected claims receipts in April and early May for its Medicaid segment, signaling continued elevated medical costs in this area, although a significant portion of Medicaid rate changes are anticipated between July and October 2024. Conversely, Centene anticipates strong performance in its Marketplace segment for 2024, including favorable risk adjustment outperformance from 2023. The Medicare segment is performing as expected. Importantly, the company's adjusted diluted EPS guidance now incorporates an estimated $125 million provision for premium deficiency reserves related to 2025 Medicare Advantage bids, to be recognized in the fourth quarter of 2024.

Centene Corporation (CNC) filed an 8-K on May 16, 2024, detailing the results of its Annual Meeting of Stockholders held on May 14, 2024. The meeting saw significant participation, with over 495 million shares of common stock represented. Key outcomes include the overwhelming election of all ten director nominees for a one-year term, demonstrating strong shareholder confidence in the current board. Additionally, the company's executive compensation plan received a non-binding advisory vote of approval, signaling shareholder support for the compensation structure. The filing also confirmed the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, a routine but important governance step. However, a shareholder proposal related to managing climate risk through science-based targets and transition planning was not approved, receiving a majority of 'against' votes. These results collectively provide insights into shareholder sentiment on board leadership, executive pay, and specific environmental governance issues.

Centene Corporation (CNC) filed an 8-K on April 26, 2024, primarily to report its financial results for the first quarter ended March 31, 2024, via an attached press release (Exhibit 99.1). While the filing itself doesn't contain detailed financial figures, it signals the company's public disclosure of its Q1 performance. Investors should refer to the press release for specific operational and financial data, including revenue, earnings, and any forward-looking guidance provided by the company. This report serves as the official notification of the Q1 2024 earnings announcement. Investors will be looking for updates on key performance indicators, such as membership growth, medical loss ratios, and profitability across its various business segments, particularly its government-sponsored health plans (Medicaid and Medicare). Any strategic initiatives or challenges discussed in the press release will also be of significant interest to the market.

Centene Corporation (CNC) reported its first quarter 2024 financial results, showcasing solid revenue growth driven by its Commercial Marketplace business. Total revenues reached $40.4 billion, a 4% increase year-over-year, primarily fueled by a 41% membership surge in its Ambetter Health product. Despite overall revenue growth, the company experienced a slight decrease in managed care membership and a nominal increase in the health benefits ratio (HBR) to 87.1%. Net earnings attributable to Centene Corporation were $1.16 billion, or $2.16 per diluted share, an increase from the prior year. The company also highlighted progress in divesting non-core international assets and expanding its Medicaid footprint in various states. Operationally, Centene is navigating the complex landscape of Medicaid redeterminations, which have impacted membership but are expected to see most states conclude by the second quarter of 2024. The company is strategically positioned to capture members transitioning from Medicaid to the Health Insurance Marketplace. While Medicare Advantage revenue saw a decline due to lower Star quality ratings, the Medicare Prescription Drug Plan (PDP) membership saw significant growth. Centene's proactive approach to market changes, ongoing value creation plan, and focus on operational efficiency provide a stable outlook despite regulatory shifts.